For the millions of individuals living with peanut allergy, risk management has long focused on oral ingestion avoidance, school nut bans, and airborne exposure — yet a quiet corner of transfusion medicine may represent an entirely unexamined hazard. This correspondence published in JAMA raises the question of whether peanut allergens can reach sensitized patients through blood transfusion products, a parenteral route conspicuously absent from clinical allergy guidelines.
The letter responds to a comprehensive review by Anagnostou and colleagues on peanut allergy management. The authors draw a pointed analogy: just as pathogens can be transmitted through transfused blood products, allergenic proteins like peanut allergens could theoretically travel the same intravenous route. The correspondence reinforces that airborne and skin-contact exposures carry minimal clinical risk — a position well-supported by existing evidence that has already led major bodies to discourage nut bans in schools and on aircraft as ineffective. The primary risk vector remains oral ingestion, but the intravenous pathway has not been systematically evaluated.
This observation sits at an underexplored intersection of transfusion medicine and clinical allergology. Peanut-specific IgE sensitization affects roughly 1–2% of the general population in Western countries, and surgical or critically ill patients with peanut allergy regularly receive blood products. Plasma, platelets, and packed red blood cells from donors who recently consumed peanuts could plausibly carry trace allergen concentrations, though no rigorous studies have yet quantified allergen loads in donor products or established whether such levels are clinically meaningful. This is a hypothesis-generating correspondence rather than an empirical study, and it lacks supporting mechanistic data or case series. Its value lies in flagging a gap in existing guidance that warrants formal investigation. For transfusion medicine and allergy specialty societies, this represents a low-cost research question with potentially high patient-safety relevance — particularly for peanut-allergic individuals undergoing elective procedures.